0

Neuroprotective Effect of the Alpha 7 Nicotinic Receptor Agonist PHA 543613 in an in Vivo Excitotoxic Adult Rat Model

Laura Foucault-Fruchard, Aurélie Doméné, Guylène Page, Marguerite Windsor, Patrick Emond, Nuno Rodrigues, Frédéric Dollé, Annelaure Damont, Frédéric Buron, Sylvain Routier, Sylvie Chalon, Daniel Antier

Neuroscience. 2017 Jul 25;356:52-63.

PMID: 28527955

Abstract:

Neuroinflammation is a key component of the pathophysiology of neurodegenerative diseases. The link between nicotine intake and positive outcome has been established, suggesting a role played by nicotinic receptors (nAChRs), especially α7nAChRs. The objective of this study was to evaluate the potential dose effects of PHA 543613 on neuron survival and striatal microglial activation in a rat model of brain excitotoxicity. A preliminary study was performed in vitro to confirm PHA 543613 agonist properties on α7nAChRs. Rats were lesioned in the right striatum with quinolinic acid (QA) and received either vehicle or PHA 543613 at 6 or 12mg/kg twice a day until sacrifice at Day 4 post-lesion. We first compared the translocator protein quantitative autoradiography in QA-lesioned brains with [3H]DPA-714 and [3H]PK-11195. The effects of PHA 543613 on microglial activation and neuronal survival were then evaluated through [3H]DPA-714 binding and immunofluorescence staining (Ox-42, NeuN) on adjacent brain sections. We demonstrated that [3H]DPA-714 provides a better signal-to-noise ratio than [3H]PK-11195. Furthermore, we showed that repeated PHA 543613 administration at a dose of 12mg/kg to QA-lesioned rats significantly protected neurons and reduced the intensity of microglial activation. This study reinforces the hypothesis that α7nAChR agonists can provide beneficial effects in the treatment of neurodegenerative diseases through potential modulation of microglial activation.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP478149530 PHA-543613 PHA-543613 478149-53-0 Price
qrcode